中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 3
Mar.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(3): 660-665

Mechanism and treatment of polycystic ovary syndrome with nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2022.03.035
  • 1a.

    Department of Hepatology, The First Hospital of Jilin University, Changchun 130021, China

  • 1b.

    Department of Pediatric Endocrinology, Genetics, and Metabolism, The First Hospital of Jilin University, Changchun 130021, China

  • 2.

    School of Basic Medical Sciences, Jilin University, Changchun 130000, China

Research funding:

Foundation of Science and Technology Commission of Jilin Province (20190201065JC)

More Information
  • Corresponding author: WEN Xiaoyu, wenxiaoyu328@aliyun.com(ORCID: 0000-0003-2109-1557)
  • Received Date: 2021-07-24
  • Accepted Date: 2021-09-16
  • Published Date: 2022-03-20
    Abstract
  • Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of childbearing age, with the clinical manifestations of oligomenorrhea or amenorrhea, hyperandrogenism, and anovulatory infertility, and it is often accompanied by metabolic disorders such as obesity, insulin resistance, hyperinsulinemia, and glucose and lipid metabolism disorders. Women with PCOS often have nonalcoholic fatty liver disease (NAFLD) and other metabolic-associated diseases, and PCOS and NAFLD are related in terms of pathogenesis and treatment. This article reviews the research advances in PCOS with NAFLD in recent years.

     

    • FullText(HTML)
  • loading
    • References(55)
  • [1]
    LI R, ZHANG Q, YANG D, et al. Prevalence of polycystic ovary syndrome in women in China: A large community-based study[J]. Hum Reprod, 2013, 28(9): 2562-2569. DOI: 10.1093/humrep/det262.
    [2]
    AZZIZ R, CARMINA E, CHEN Z, et al. Polycystic ovary syndrome[J]. Nat Rev Dis Primers, 2016, 2: 16057. DOI: 10.1038/nrdp.2016.57.
    [3]
    National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association, Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease: A 2018 update[J]. J Clin Hepatol, 2018, 34(5): 947-957. DOI: 10.3969/j.issn.1001-5256.2018.05.007

    中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018, 34(5): 947-957. DOI: 10.3969/j.issn.1001-5256.2018.05.007
    [4]
    ZENG J, FAN JG. Clinical significance of renaming nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2020, 36(6): 1205-1207. DOI: 10.3969/j.issn.1001-5256.2020.06.002.

    曾静, 范建高. 非酒精性脂肪性肝病更名的临床意义[J]. 临床肝胆病杂志, 2020, 36(6): 1205-1207. DOI: 10.3969/j.issn.1001-5256.2020.06.002.
    [5]
    PASCHOU SA, POLYZOS SA, ANAGNOSTIS P, et al. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome[J]. Endocrine, 2020, 67(1): 1-8. DOI: 10.1007/s12020-019-02085-7.
    [6]
    QU Z, ZHU Y, JIANG J, et al. The clinical characteristics and etiological study of nonalcoholic fatty liver disease in Chinese women with PCOS[J]. Iran J Reprod Med, 2013, 11(9): 725-732.
    [7]
    PETTA S, CIRESI A, BIANCO J, et al. Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS[J]. PLoS One, 2017, 12(11): e0186136. DOI: 10.1371/journal.pone.0186136.
    [8]
    SARKAR M, TERRAULT N, CHAN W, et al. Polycystic ovary syndrome (PCOS) is associated with NASH severity and advanced fibrosis[J]. Liver Int, 2020, 40(2): 355-359. DOI: 10.1111/liv.14279.
    [9]
    BALLESTRI S, ZONA S, TARGHER G, et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis[J]. J Gastroenterol Hepatol, 2016, 31(5): 936-944. DOI: 10.1111/jgh.13264.
    [10]
    YOUNOSSI ZM, KOENIG AB, ABDELATIF D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64(1): 73-84. DOI: 10.1002/hep.28431.
    [11]
    SAKURAI Y, KUBOTA N, YAMAUCHI T, et al. Role of insulin resistance in MAFLD[J]. Int J Mol Sc, 2021, 22(8): 4156. DOI: 10.3390/ijms22084156.
    [12]
    LEGRO RS, CASTRACANE VD, KAUFFMAN RP. Detecting insulin resistance in polycystic ovary syndrome: Purposes and pitfalls[J]. Obstet Gynecol Surv, 2004, 59(2): 141-154. DOI: 10.1097/01.OGX.0000109523.25076.E2.
    [13]
    DIAMANTI-KANDARAKIS E, DUNAIF A. Insulin resistance and the polycystic ovary syndrome revisited: An update on mechanisms and implications[J]. Endocr Rev, 2012, 33(6): 981-1030. DOI: 10.1210/er.2011-1034.
    [14]
    QU X, DONNELLY R. Sex hormone-binding globulin (SHBG) as an early biomarker and therapeutic target in polycystic ovary syndrome[J]. Int J Mol Sci, 2020, 21(21): 8191. DOI: 10.3390/ijms21218191.
    [15]
    FENG C, JIN Z, CHI X, et al. SHBG expression is correlated with PI3K/AKT pathway activity in a cellular model of human insulin resistance[J]. Gynecol Endocrinol, 2018, 34(7): 567-573. DOI: 10.1080/09513590.2017.1411474.
    [16]
    SIMÓ R, SAEZ-LOPEZ C, LECUBE A, et al. Adiponectin upregulates SHBG production: Molecular mechanisms and potential implications[J]. Endocrinology, 2014, 155(8): 2820-2830. DOI: 10.1210/en.2014-1072.
    [17]
    SALVA-PASTOR N, CHÁVEZ-TAPIA NC, URIBE M, et al. Understanding the association of polycystic ovary syndrome and non-alcoholic fatty liver disease[J]. J Steroid Biochem Mol Biol, 2019, 194: 105445. DOI: 10.1016/j.jsbmb.2019.105445.
    [18]
    ROSENFIELD RL, EHRMANN DA. The pathogenesis of polycystic ovary syndrome (PCOS): The hypothesis of PCOS as functional ovarian hyperandrogenism revisited[J]. Endocr Rev, 2016, 37(5): 467-520. DOI: 10.1210/er.2015-1104.
    [19]
    QIAO PY, WANG XP, YANG SS, et al. Changes of sex hormones in patients with PCOS before and after treatment and their relationship with insulin resistance and obesity[J]. J Clin Exp Med, 2022, 21(1): 62-65. DOI: 10.3969/j.issn.1671-4695.2022.01.017.

    乔鹏艳, 王仙萍, 杨姗姗, 等. PCOS患者治疗前后性激素的变化及其与胰岛素抵抗、肥胖的关系[J]. 临床和实验医学杂志, 2022, 21(1): 62-65. DOI: 10.3969/j.issn.1671-4695.2022.01.017.
    [20]
    ROCHA A, FARIA LC, GUIMARÃES T, et al. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: Systematic review and meta-analysis[J]. J Endocrinol Invest, 2017, 40(12): 1279-1288. DOI: 10.1007/s40618-017-0708-9.
    [21]
    SARKAR M, TERRAULT N, CHAN W, et al. Polycystic ovary syndrome (PCOS) is associated with NASH severity and advanced fibrosis[J]. Liver Int, 2020, 40(2): 355-359. DOI: 10.1111/liv.14279.
    [22]
    LI T, ZHANG T, CUI T, et al. Involvement of endogenous testosterone in hepatic steatosis in women with polycystic ovarian syndrome[J]. J Steroid Biochem Mol Biol, 2020, 204: 105752. DOI: 10.1016/j.jsbmb.2020.105752.
    [23]
    ADEYANJU OA, FALODUN TO, MICHAEL OS, et al. Spironolactone reversed hepato-ovarian triglyceride accumulation caused by letrozole-induced polycystic ovarian syndrome: Tissue uric acid-a familiar foe[J]. Naunyn Schmiedebergs Arch Pharmacol, 2020, 393(6): 1055-1066. DOI: 10.1007/s00210-020-01809-1.
    [24]
    CUI P, HU W, MA T, et al. Long-term androgen excess induces insulin resistance and non-alcoholic fatty liver disease in PCOS-like rats[J]. J Steroid Biochem Mol Biol, 2021, 208: 105829. DOI: 10.1016/j.jsbmb.2021.105829.
    [25]
    SEIDU T, MCWHORTER P, MYER J, et al. DHT causes liver steatosis via transcriptional regulation of SCAP in normal weight female mice[J]. J Endocrinol, 2021, 250(2): 49-65. DOI: 10.1530/JOE-21-0040.
    [26]
    PASQUALI R, ORIOLO C. Obesity and androgens in women[J]. Front Horm Res, 2019, 53: 120-134. DOI: 10.1159/000494908.
    [27]
    OGUZ SH, I·DILMAN I, HELVACI N, et al. Tissue fat quantification by magnetic resonance imaging: Proton density fat fraction in polycystic ovary syndrome[J]. Reprod Biomed Online, 2020, 41(2): 329-334. DOI: 10.1016/j.rbmo.2020.04.024.
    [28]
    YE W, XIE T, SONG Y, et al. The role of androgen and its related signals in PCOS[J]. J Cell Mol Med, 2021, 25(4): 1825-1837. DOI: 10.1111/jcmm.16205.
    [29]
    YU JL, HOU LH, SUN M, et al. Difference analysis of clinical characteristics of polycystic ovary syndrome patients with different body mass index[J]. China Med Herald, 2020, 17(26): 75-78. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202026020.htm

    于婧璐, 侯丽辉, 孙淼, 等. 不同体重指数的多囊卵巢综合征患者的临床特征差异性分析[J]. 中国医药导报, 2020, 17(26): 75-78. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202026020.htm
    [30]
    Endocrine Study Group and Expert Group, Chinese Society of Obstetrics and Gynecology, Chinese Medical Association. Chinese guidelines for the diagnosis and treatment of polycystic ovary syndrome[J]. Chin J Obstetr Gynecol, 2018, 53(1): 2-6. DOI: 10.3760/cma.j.issn.0529-567x.2018.01.002.

    中华医学会妇产科学分会内分泌学组及指南专家组. 多囊卵巢综合征中国诊疗指南[J]. 中华妇产科杂志, 2018, 53(1): 2-6. DOI: 10.3760/cma.j.issn.0529-567x.2018.01.002.
    [31]
    AYONRINDE OT, ODDY WH, ADAMS LA, et al. Infant nutrition and maternal obesity influence the risk of non-alcoholic fatty liver disease in adolescents[J]. J Hepatol, 2017, 67(3): 568-576. DOI: 10.1016/j.jhep.2017.03.029.
    [32]
    GANGALE MF, MIELE L, LANZONE A, et al. Long-term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome[J]. Clin Endocrinol (Oxf), 2011, 75(4): 520-527. DOI: 10.1111/j.1365-2265.2011.04093.x.
    [33]
    TAN S, VOLLMAR N, BENSON S, et al. Liver injury indicating fatty liver but not serologic NASH marker improves under metformin treatment in polycystic ovary syndrome[J]. Int J Endocrinol, 2015, 2015: 254169. DOI: 10.1155/2015/254169.
    [34]
    IBÁÑEZ L, DEL RÍO L, DÍAZ M, et al. Normalizing ovulation rate by preferential reduction of hepato-visceral fat in adolescent girls with polycystic ovary syndrome[J]. J Adolesc Health, 2017, 61(4): 446-453. DOI: 10.1016/j.jadohealth.2017.04.010.
    [35]
    XU Y, WU Y, HUANG Q. Comparison of the effect between pioglitazone and metformin in treating patients with PCOS: A meta-analysis[J]. Arch Gynecol Obstet, 2017, 296(4): 661-677. DOI: 10.1007/s00404-017-4480-z.
    [36]
    VALSAMAKIS G, LOIS K, KUMAR S, et al. Metabolic and other effects of pioglit-azone as an add-on therapy to metformin in the treatment of polycystic ovary syndrome (PCOS)[J]. Hormones (Athens), 2013, 12(3): 363-78. DOI: 10.1007/BF03401302.
    [37]
    KAHAL H, ABOUDA G, RIGBY AS, et al. Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease[J]. Clin Endocrinol (Oxf), 2014, 81(4): 523-528. DOI: 10.1111/cen.12369.
    [38]
    FRØSSING S, NYLANDER M, CHABANOVA E, et al. Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial[J]. Diabetes Obes Metab, 2018, 20(1): 215-218. DOI: 10.1111/dom.13053.
    [39]
    SIAMASHVILI M, DAVIS SN. Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome[J]. Expert Rev Clin Pharmacol, 2021, 14(9): 1081-1089. DOI: 10.1080/17512433.2021.1933433.
    [40]
    NEWSOME PN, BUCHHOLTZ K, CUSI K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis[J]. N Engl J Med, 2021, 384(12): 1113-1124. DOI: 10.1056/NEJMoa2028395.
    [41]
    YARIBEYGI H, SATHYAPALAN T, MALEKI M, et al. Molecular mechanisms by which SGLT2 inhibitors can induce insulin sensitivity in diabetic milieu: A mechanistic review[J]. Life Sci, 2020, 240: 117090. DOI: 10.1016/j.lfs.2019.117090.
    [42]
    MANTOVANI A, BYRNE CD, SCORLETTI E, et al. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials[J]. Diabetes Metab, 2020, 46(6): 427-441. DOI: 10.1016/j.diabet.2019.12.007.
    [43]
    SEKO Y, NISHIKAWA T, UMEMURA A, et al. Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1-3 fibrosis[J]. Diabetes Metab Syndr Obes, 2018, 11: 835-843. DOI: 10.2147/DMSO.S184767.
    [44]
    ITANI T, ISHIHARA T. Efficacy of canagliflozin against nonalcoholic fatty liver disease: A prospective cohort study[J]. Obes Sci Pract, 2018, 4(5): 477-482. DOI: 10.1002/osp4.294.
    [45]
    OLANIYI KS, ONIYIDE AA, ADEYANJU OA, et al. Low dose spironolactone-mediated androgen-adiponectin modulation alleviates endocrine-metabolic disturbances in letrozole-induced PCOS[J]. Toxicol Appl Pharmacol, 2021, 411: 115381. DOI: 10.1016/j.taap.2020.115381.
    [46]
    PANI A, GIOSSI R, MENICHELLI D, et al. Inositol and non-alcoholic fatty liver disease: A systematic review on deficiencies and supplementation[J]. Nutrients, 2020, 12(11). DOI: 10.3390/nu12113379.
    [47]
    GAN WJ, LI G. Ovulation induction in the treatment of patients with polycystic ovary syndrome[J]. Chin J Reproduct Contracept, 2019, (4): 322-324. DOI: 10.3760/cma.j.issn.2096-2916.2019.04.012.

    甘文锦, 李刚. 多囊卵巢综合征患者促排卵治疗的研究进展[J]. 中华生殖与避孕杂志, 2019, 39(4): 322-324. DOI: 10.3760/cma.j.issn.2096-2916.2019.04.012.
    [48]
    LEE E, LIM Y, KWON SW, et al. Pinitol consumption improves liver health status by reducing oxidative stress and fatty acid accumulation in subjects with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial[J]. J Nutr Biochem, 2019, 68: 33-41. DOI: 10.1016/j.jnutbio.2019.03.006.
    [49]
    KALYANARAMAN R, PAL L. A narrative review of current understanding of the pathophysiology of polycystic ovary syndrome: Focus on plausible relevance of vitamin D[J]. Int J Mol Sci, 2021, 22(9): 4905. DOI: 10.3390/ijms22094905.
    [50]
    AL-BAYYARI N, AL-DOMI H, ZAYED F, et al. Androgens and hirsutism score of overweight women with polycystic ovary syndrome improved after vitamin D treatment: A randomized placebo controlled clinical trial[J]. Clin Nutr, 2021, 40(3): 870-878. DOI: 10.1016/j.clnu.2020.09.024.
    [51]
    MENG J, ZHU Y. Efficacy of simvastatin plus metformin for polycystic ovary syndrome: A meta-analysis of randomized controlled trials[J]. Eur J Obstet Gynecol Reprod Biol, 2021, 257: 19-24. DOI: 10.1016/j.ejogrb.2020.11.070.
    [52]
    XIA Y, WANG Y, CUI M, et al. Efficacy of omega-3 fatty acid supplementation on cardiovascular risk factors in patients with polycystic ovary syndrome: A systematic review and meta-analysis[J]. Ann Palliat Med, 2021, 10(6): 6425-6437. DOI: 10.21037/apm-21-1050.
    [53]
    CLIMAX J, NEWSOME PN, HAMZA M, et al. Effects of epeleuton, a novel synthetic second-generation n-3 fatty acid, on non-alcoholic fatty liver disease, triglycerides, glycemic control, and cardiometabolic and inflammatory markers[J]. J Am Heart Assoc, 2020, 9(16): e016334. DOI: 10.1161/JAHA.119.016334.
    [54]
    CHUDZICKA-STRUGAŁA I, KUBIAK A, BANASZEWSKA B, et al. Effects of synbiotic supplementation and lifestyle modifications on women with polycystic ovary syndrome[J]. J Clin Endocrinol Metab, 2021, 106(9): 2566-2573. DOI: 10.1210/clinem/dgab369.
    [55]
    ARON-WISNEWSKY J, WARMBRUNN MV, NIEUWDORP M, et al. Nonalcoholic fatty liver disease: Modulating gut microbiota to improve severity?[J]. Gastroenterology, 2020, 158(7): 1881-1898. DOI: 10.1053/j.gastro.2020.01.049.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (657) PDF downloads(60) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return